The document discusses three topics: 1. NWT-02, a product containing lutein from egg yolks that has shown to efficiently increase lutein levels in the blood and macula, leading to stabilization of eye functions. Clinical trials show little effect on cholesterol. 2. NWT-03, bioactive peptides from egg proteins designed to reduce blood pressure and maintain vascular flexibility. Studies in animals confirm these effects. 3. Newtricious' role in cross-sector prevention by developing specialized foods and linking science, innovation, lifestyle and healthcare through partnerships.

1. Lifestyle & Food
Voorkomen is het nieuwe genezen
Health Valley Event
Luc Sterkman 13 maart 2013

2. Nelissen Pluimvee

3. Globus ei BV

4. Prijsvorming
1,4
Prijs per kilo
1,2
1
0,8
2003
2004
2005
0,6
0,4
0,2
0
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52
Week

5. Zoektocht naar toegevoegde waarde

6. Begin van nieuw leven!

8. Preventie
Genetica
Voeding
Leefstijl
Gezondheidszorg

9. Health Valley 2013
Health Valley, make health & innovation work!

10. Innovatie

11. Innovatie 2.0

13. Medication
Nutraceutical
Food

15. Ontwikkelprogramma’s
NWT-02
Bioactive peptides
NWT-03 Behoud van cardiovasculaire
gezondheid
OBESITAS

16. Pharmaceutical approach
Aangepast op regelgeving
Senior farma medewerkers
Klinische studies
Product ontwikkeling
Kwaliteits standaard
– Good Clinical Practice
– Good Laboratory Practice
– Good Manufacturing Practice

18. New regulation (2006/1924/EC)
Voedingsclaims Gezondheidsclaims
Art. 13 Art. 14
Art. 13.1 Art. 13.5 Art. 14
Bijv. Nutriënt
samenstelling Algemeen Claim op basis - Risico reductie
geaccepteerd van ‘nieuw’ - Kinderen
wetenschap- bewijs
pelijk bewijs

19. Business model

20. Egg yolk is the superior carrier for lutein
Chung, HY, et al, J. Nutr. 134:1887-1893, 2004

21. NWT-02 status
2007 2012 2014
PCT
National
Patents EU filing PCT filing grant
authorizations
ed
EFSA/
Regulatory Lab Volunteers People “at risk’’
FDA
Production Lab scale Pilot scale Industrial
Market
Marketing definition
Product definition Preparations Partnering Sales

22. Clinical trial program
Human 1 - pivotal study on visual function
12 months | 100 subjects with early stage AMD
Human 2 - study on cholesterol & AMD
3 months | 120 healthy volunteers
Human 3 - study on bioavailability of ‘EyePowder’
formulations vs NWT-02
2 months | 100 healthy volunteers
Human 4 - pivotal study on visual function
12 months | 120 subjects - early stage AMD

24. NWT-02 results – pilot study
Blood lutein level Total Cholesterol
2,00 1,04
1,03
1,80
1,02
Change vs base line
Change vs base line
Normal egg Normal egg
1,60 1,01
NWT-02 NWT-02
1,00
1,40
NWT-01 (lutein 0,99 NWT-01 (lutein
egg) egg)
1,20 Control 0,98 Control
0,97
1,00
0,96
0,80 0,95
0w 6,5 w 13 weeks 0w 6,5 w 13 weeks
Time Time

26. Results
NWT-02 does very efficiently bring lutein and other valuable
nutrients in the blood stream and into the macula.
This leads to stabilization (often even improvement) of eye
functions such as visual acuity and light- dark adaptation.
Although egg yolk is used, there is no or little effect on
blood cholesterol.

27. NWT-03: “the new approach
for maintaining (vascular) health”
Development of bioactive peptides as functional food or nutraceutical for
the prevention of vascular damage and related disorders

28. NWT-03 Project
Hydrolysate – produced via enzymatic treatment of lysozyme, an egg-
derived protein
Designed based on bioinformatics-model of the University Wageningen;
aiming for a beneficial effect on the arterial vascular wall
First tested in pharmacology models to confirm the effect and elucidate
the mechanisms
Subsequently tested in animal experiments:
– Confirming reduction in bloodpressure in Hypertensive rats
– Demonstrating maintenance of the flexibility of the vascular wall in
ZDF-rats, which suffer from Diabetes melllitus; model for ageing

29. NWT-03 status
2006 2012 2015
Patents PCT National
EU filing PCT filing
granted authorizations
Regulatory Lab Animals Volunteers Patients EFSA/ FDA
Production Lab scale Pilot scale Industrial
Market
Marketing definition
Product definition Preparations Partnering Sales

30. Acute effects of NWT-03 in SHR-rats

31. Kidney – anatomy and histology
Histology (PAS) of a
healthy glomerulus

32. Renal morphology in ZDF-rats

33. Glomerulosclerosis and Albuminuria
60
50
glomerulosclerosis-score
40
9
controls
30 8 diabetes
Albuminurie (mg/24uur) 7
diabetes + NWT-03
20
6
controles
10 5
diabetes
4 diabetes + NWT-03
0
3
2
1
0

35. Sector overschrijdende aanpak
Genetica
Wetenschap
Innovatieve bedrijven
Voeding
Leefstijl
Overheid
Gezondheidszorg

36. Preventieve aanpak
Diagnostiek
Genetica
Wetenschap
Innovatieve bedrijven
Voeding
Speciale voeding
Leefstijl
Overheid
Preventiemanagement
Gezondheidszorg
Zorgverzekeraars

37. Secundaire preventie
Vroege diagnostiek Medische technologie
– Kan leiden tot
– Kan leiden tot
Vroege behandeling Diagnostische apparatuur
– Met als doel
– Met als doel
Secundaire preventie Vroege diagnostiek
– Gebruik makend van
– Gebruik makend van
Food Scanning Laser Optics
– Milde effecten
– Milde methode
– Zonder neven effecten
– Zonder neven effecten
– Op professionele wijze
– Op professionele wijze
ontwikkeld (farma)
ontwikkeld (Qserve)

38. Rol Newtricious

39. Samenwerken

40. Samenwerken en verbinden

41. Virtual company

42. Newtricious “Network”
Nateland consultancy
Coppelmans VOF

43. BrandRep
Aroma Uden

44. Strategische investeerders